Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velaglucerase beta enzyme replacement therapy in pediatric Gaucher disease
CTR20263097Phase 3Active
- Sponsor
- CANbridge Pharmaceuticals Inc.
- Start
- Aug 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of velaglucerase beta in Gaucher disease type 1 (GD1), Gaucher disease type 3, sponsored by CANbridge Pharmaceuticals Inc.. Started Aug 2026; status: active.
02
Drugs
velaglucerase beta
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on CTR20263097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263097.